kashbiotech

Progress in Gynecologic Cancers with Antibody Drug Conjugates

 Objective of evaluate: This text supplies a complete evaluate of antibody-drug conjugates (ADCs) beneath investigation in gynecologic cancers. The construction and performance of ADCs are reviewed with a deal with medical profit in addition to toxicity profiles.

Latest findings: A number of ADCs with varied goal antigens have been investigated in ovarian, cervical, and endometrial most cancers. ADCs have constantly demonstrated favorable security/tolerability profiles each as monotherapy and together remedy. In ovarian most cancers, response charges have ranged from 9 to 46% for monotherapy with response charges as excessive as 83% together remedy. In sufferers with cervical most cancers with progressive illness regardless of doublet remedy and bevacizumab, response charges as excessive as 24% have been noticed. ADCs characterize a quickly evolving area of focused remedy which have demonstrated notable medical profit each as monotherapy but additionally together remedy with an general favorable toxicity profile. With continued refinement of the goal biomarkers utilized, improved medical profit is more likely to be noticed.

Low seroprevalence of SARS-CoV-2 antibodies in a liver transplant cohort

 

Stable organ transplant recipients would possibly be at larger threat for acquisition and mortality on account of SARS-CoV-2. There isn’t a knowledge concerning SARS-CoV-2 seroprevalence amongst liver transplant (LT) recipients, and whether or not it’s totally different from that of the final inhabitants or different immunosuppressed teams. We evaluated the prevalence of IgG SARS-CoV-2 antibodies amongst LT recipients to estimate the frequency of asymptomatic SARS-CoV-2 an infection utilizing serological assays in our outpatient clinic. We performed a cross-sectional evaluation from Could 10th to October 26th 2020 of all grownup (>18 years) LT recipients that underwent a routine laboratory check for the outpatient clinic follow-up on the Hospital Universitari Vall d’Hebron (Barcelona) during which we included serological testing for SARS-CoV-2. 9 out of 294 LT recipients (3.1%) examined optimistic for anti-SARS-CoV-2 IgG antibodies.

5 of them (55.5%) had suffered clinically symptomatic SARS-CoV2 an infection confirmed by RT-PCR, 4 (44.4%) had offered suitable signs however with out microbiological affirmation and just one affected person (1/9, 11.1%) examined optimistic with none earlier symptom. SARS-CoV-2 seroprevalence amongst LT recipients in an space extremely affected by the pandemic is decrease than within the basic inhabitants in the identical space. These outcomes render the potential of asymptomatic an infection in LT recipients not possible.

Novel antibody cocktail concentrating on Guess v 1 quickly and sustainably treats birch allergy signs in a Part 1 examine

 

Background: The efficacy of an allergen-specific IgG cocktail to deal with cat allergy means that allergen-specific IgG could also be a significant protecting mechanism elicited by allergen immunotherapy.

Goal: Extending these findings, we examined a Guess v 1-specific antibody cocktail in birch-allergic topics.

Strategies: Part 1, randomized, double-blind, examine: Half-A, ascending doses of Guess v 1-specific antibody cocktail “REGN5713/14/15” (150-900 mg) in 32 wholesome adults; Half-B, single subcutaneous 900 mg dose or placebo in 64 birch-allergic topics. Complete nasal symptom rating (TNSS) response to titrated birch extract nasal allergen problem (NAC) and pores and skin prick check (SPT) with birch and alder allergen have been assessed at screening and days 8, 29, 57 and 113 (SPT solely); basophil activation checks (n=26) have been performed.

Outcomes: Single dose REGN5713/14/15 considerably diminished TNSS following birch NAC relative to baseline. Variations in TNSS AUC(0-1 hr) versus placebo (day 8: -1.17, P = .001; day 29: -1.18, P = .001; day 57: -0.85, P = .024) and titration SPT with birch distinction in AUC of imply wheal diameters versus placebo (all P < .001) have been sustained for ≥2 months; comparable outcomes noticed with alder SPT. REGN5713/14/15 was well-tolerated. Basophil responsiveness to birch-related allergens was considerably decreased in REGN5713/14/15-treated topics versus placebo on days 8, 57, and 113 (all P < .01).

Conclusion: Single dose REGN5713/14/15 was effectively tolerated and offered a speedy (1 week) and sturdy (2 months) discount in allergic signs after birch allergen NAC, probably providing a brand new paradigm for the remedy of birch allergy signs.

Transfusion-induced platelet antibodies and regulatory T cells in multiply transfused sufferers

Background: Platelet transfusion refractoriness (PTR) stays a tough drawback in sufferers requiring long-term platelet supportive care. Nonetheless, there are little knowledge on the frequency of platelet antibodies in multiply transfused Chinese language sufferers. Furthermore, the connection between peripheral regulatory T cells (Tregs) and PTR stays unclear.

Strategies: We retrospectively studied the frequency of alloimmunization towards platelet antigens in sufferers receiving a number of transfusions between 2013 and 2017. Monoclonal antibody solid-phase platelet antibody check (MASPAT) kits have been used to display screen for platelet antibodies earlier than every platelet transfusion. Peripheral Tregs and CD4+ CD25+ CD127 T cells have been detected by circulate cytometry, whereas reworking progress factor-beta (TGF-β) and interleukin (IL)-17 cytokines have been detected by enzyme-linked immunosorbent assay.

Outcomes: A complete of 399 sufferers who met the inclusion standards have been enrolled for the evaluation of platelet antibodies and refractoriness. Amongst these sufferers, 10 (2.5%) have been optimistic for platelet antibodies earlier than transfusion and 47 (11.8%) grew to become antibody-positive throughout the examine interval. The variety of alloimmunized sufferers was considerably greater in sufferers with hematological illness as in contrast with different illness teams (p < 0.05). Refractoriness and alloimmunization occurred in 77 (19.3%) and 22 (28.6%) sufferers, respectively. There have been no vital variations in CD4+ , CD8+ , and CD4+ CD25+ CD127 T cell numbers and plasma ranges of TGF-β1 and IL-17 between sufferers with PTR and the management group.

Conclusions: Refractoriness was frequent in sufferers present process a number of platelet transfusions (19.3%), with alloimmunization noticed in 28.6% of sufferers. Nonetheless, Tregs in peripheral blood might not play a key position in PTR.

kashbiotech
kashbiotech

Younger infants exhibit strong purposeful antibody responses and restrained IFN-γ manufacturing to SARS-CoV-2

 

Extreme COVID-19 seems uncommon in kids. That is surprising, particularly in younger infants, who’re susceptible to extreme illness attributable to different respiratory viruses. We consider convalescent immune responses in 4 infants beneath 3 months previous with confirmed COVID-19 who offered with delicate febrile sickness, alongside their dad and mom, and grownup controls recovered from confirmed COVID-19.

Though not statistically vital, in comparison with seropositive adults, infants have excessive serum ranges of IgG and IgA to SARS-CoV-2 spike protein with corresponding purposeful skill to dam SARS-CoV-2 mobile entry. Infants additionally exhibit strong saliva anti-spike IgG and IgA responses. Spike-specific IFN-γ manufacturing by toddler peripheral blood mononuclear cells seems restrained, however the frequency of spike-specific IFN-γ and/or TNF-ɑ producing T cells is comparable between infants and adults. On principal part evaluation, toddler immune responses seem distinct from their dad and mom. Sturdy purposeful antibody responses alongside restrained IFN-γ manufacturing might assist defend infants from extreme COVID-19.

Salivary IgA antibody to malondialdehyde-acetaldehyde associates with delicate periodontal pocket depth

 

Goal: Oxidized epitopes reminiscent of malondialdehyde-acetaldehyde (MAA) play an important position within the development of atherosclerosis by way of activation of the humoral immune response. The precise mechanism of the affiliation between atherosclerosis and periodontal illnesses shouldn’t be totally understood. The purpose of the present examine is to judge the affiliation of oral humoral immune response to oxidized epitopes with parameters of periodontal illness.

Supplies and strategies: The Parogene cohort encompass sufferers who’ve undergone coronary angiography on account of cardiac signs. On this examine, 423 sufferers have been randomly chosen for an in depth oral examination. Salivary Immunoglobulin A to oxidized epitopes and bacterial antigens was decided by chemiluminescence immunoassay.

Outcomes: In a binary logistic regression mannequin adjusted with periodontal illness confounders, periodontal pocket depth (PPD) 4-5 mm related to salivary IgA antibodies to MAA-LDL (p = 0.034), warmth shock protein 60 of Aggregatibacter actinomycetemcomitans (p = 0.045), Porphyromonas gingivalis (p = 0.045), A. actinomycetemcomitans (p = 0.005), P. intermedia (p = 0.020), and complete IgA (p = 0.003).

Conclusions: The present examine reveals the affiliation of salivary IgA to MAA-LDL with PPD 4-5 mm in a cohort of sufferers with continual coronary artery illness. Humoral immune cross-reactivation to oxidized epitopes such MAA-LDL may partly clarify the hyperlink of periodontitis with systemic illnesses.

 

anti-LIF

YF-PA12952 50 ug
EUR 363
Description: Mouse polyclonal to LIF

Bovine Leukemia Inhibitory Factor (LIF) ELISA Kit

RD-LIF-b-48Tests 48 Tests
EUR 555

Bovine Leukemia Inhibitory Factor (LIF) ELISA Kit

RD-LIF-b-96Tests 96 Tests
EUR 771

Canine Leukemia Inhibitory Factor (LIF) ELISA Kit

RD-LIF-c-48Tests 48 Tests
EUR 533

Canine Leukemia Inhibitory Factor (LIF) ELISA Kit

RD-LIF-c-96Tests 96 Tests
EUR 740

Human Leukemia Inhibitory Factor (LIF) ELISA Kit

RD-LIF-Hu-48Tests 48 Tests
EUR 367

Human Leukemia Inhibitory Factor (LIF) ELISA Kit

RD-LIF-Hu-96Tests 96 Tests
EUR 502

Porcine Leukemia Inhibitory Factor (LIF) ELISA Kit

RD-LIF-p-48Tests 48 Tests
EUR 555

Porcine Leukemia Inhibitory Factor (LIF) ELISA Kit

RD-LIF-p-96Tests 96 Tests
EUR 771

Rat Leukemia Inhibitory Factor (LIF) ELISA Kit

RD-LIF-Ra-48Tests 48 Tests
EUR 511

Rat Leukemia Inhibitory Factor (LIF) ELISA Kit

RD-LIF-Ra-96Tests 96 Tests
EUR 709

Bovine Leukemia Inhibitory Factor (LIF) ELISA Kit

DLR-LIF-b-48T 48T
EUR 547
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates or other biological fluids.

Bovine Leukemia Inhibitory Factor (LIF) ELISA Kit

DLR-LIF-b-96T 96T
EUR 715
Description: A sandwich quantitative ELISA assay kit for detection of Bovine Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates or other biological fluids.

Canine Leukemia Inhibitory Factor (LIF) ELISA Kit

DLR-LIF-c-48T 48T
EUR 527
Description: A sandwich quantitative ELISA assay kit for detection of Canine Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Canine Leukemia Inhibitory Factor (LIF) ELISA Kit

DLR-LIF-c-96T 96T
EUR 688
Description: A sandwich quantitative ELISA assay kit for detection of Canine Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Human Leukemia Inhibitory Factor (LIF) ELISA Kit

DLR-LIF-Hu-48T 48T
EUR 380
Description: A sandwich quantitative ELISA assay kit for detection of Human Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Human Leukemia Inhibitory Factor (LIF) ELISA Kit

DLR-LIF-Hu-96T 96T
EUR 485
Description: A sandwich quantitative ELISA assay kit for detection of Human Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Porcine Leukemia Inhibitory Factor (LIF) ELISA Kit

DLR-LIF-p-48T 48T
EUR 547
Description: A sandwich quantitative ELISA assay kit for detection of Porcine Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates or other biological fluids.

Porcine Leukemia Inhibitory Factor (LIF) ELISA Kit

DLR-LIF-p-96T 96T
EUR 715
Description: A sandwich quantitative ELISA assay kit for detection of Porcine Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates or other biological fluids.

Rat Leukemia Inhibitory Factor (LIF) ELISA Kit

DLR-LIF-Ra-48T 48T
EUR 508
Description: A sandwich quantitative ELISA assay kit for detection of Rat Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Rat Leukemia Inhibitory Factor (LIF) ELISA Kit

DLR-LIF-Ra-96T 96T
EUR 661
Description: A sandwich quantitative ELISA assay kit for detection of Rat Leukemia Inhibitory Factor (LIF) in samples from serum, plasma, tissue homogenates, cell lysates, cell culture supernates or other biological fluids.

Bovine Leukemia Inhibitory Factor (LIF) ELISA Kit

RDR-LIF-b-48Tests 48 Tests
EUR 580

Bovine Leukemia Inhibitory Factor (LIF) ELISA Kit

RDR-LIF-b-96Tests 96 Tests
EUR 807

Canine Leukemia Inhibitory Factor (LIF) ELISA Kit

RDR-LIF-c-48Tests 48 Tests
EUR 557

Canine Leukemia Inhibitory Factor (LIF) ELISA Kit

RDR-LIF-c-96Tests 96 Tests
EUR 774

Human Leukemia Inhibitory Factor (LIF) ELISA Kit

RDR-LIF-Hu-48Tests 48 Tests
EUR 383

Human Leukemia Inhibitory Factor (LIF) ELISA Kit

RDR-LIF-Hu-96Tests 96 Tests
EUR 525

Porcine Leukemia Inhibitory Factor (LIF) ELISA Kit

RDR-LIF-p-48Tests 48 Tests
EUR 580

Porcine Leukemia Inhibitory Factor (LIF) ELISA Kit

RDR-LIF-p-96Tests 96 Tests
EUR 807

Rat Leukemia Inhibitory Factor (LIF) ELISA Kit

RDR-LIF-Ra-48Tests 48 Tests
EUR 534

Rat Leukemia Inhibitory Factor (LIF) ELISA Kit

RDR-LIF-Ra-96Tests 96 Tests
EUR 742

Rabbit Polyclonal antibody Anti-CRBN

Anti-CRBN 50 µg
EUR 349

Anti-LIF Antibody

PA1562 100ug/vial
EUR 294

Anti-LIF Antibody

PB9036 100ug/vial
EUR 334

Anti-LIF antibody

STJ29846 100 µl
EUR 277
Description: The protein encoded by this gene is a pleiotropic cytokine with roles in several different systems. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, induction of neuronal cell differentiation, regulator of mesenchymal to epithelial conversion during kidney development, and may also have a role in immune tolerance at the maternal-fetal interface. Alternatively spliced transcript variants encoding multiple isoforms have been observed for this gene.

Anti-LIF Antibody

A01400 100ug/vial
EUR 294

Anti-LIF antibody

STJ96472 200 µl
EUR 197
Description: Rabbit polyclonal to LIF.

Anti-LIF antibody

STJ73631 100 µg
EUR 359

anti- LIF antibody

FNab09804 100µg
EUR 548.75
Description: Antibody raised against LIF

anti- LIF antibody

LSMab09804 100 ug
EUR 386

LIF, Mouse

HY-P7084 50ug
EUR 533

LIF, mouse

MO16102 100 ug
EUR 675

Anti-LIF (aa28-39) antibody

STJ72919 100 µg
EUR 359

Polyclonal Goat anti-GST α-form

GST-ANTI-1 50 uL
EUR 280

Polyclonal Goat anti-GST μ-form

GST-ANTI-2 50 uL
EUR 280

Polyclonal Goat anti-GST p-form

GST-ANTI-3 50 uL
EUR 280

Recombinant Mouse LIF Protein

R01400-1 100ug/vial
EUR 294

Mouse LIF ELISA Kit

EML0014 96Tests
EUR 521

Mouse LIF shRNA Plasmid

20-abx971321
  • EUR 801.00
  • EUR 1121.00
  • 150 µg
  • 300 µg

LIF Antibody

1-CSB-PA198481
  • EUR 317.00
  • EUR 244.00
  • 100ul
  • 50ul
Description: A polyclonal antibody against LIF. Recognizes LIF from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:10000, IHC:1:25-1:100

LIF Antibody

1-CSB-PA012928ESR2HU
  • EUR 222.00
  • EUR 335.00
  • 100ul
  • 50ul
Description: A polyclonal antibody against LIF. Recognizes LIF from Human. This antibody is Unconjugated. Tested in the following application: ELISA

LIF Antibody

1-CSB-PA004761
  • EUR 222.00
  • EUR 195.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against LIF. Recognizes LIF from Human. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/20000

LIF, Human

HY-P7049 10ug
EUR 1600

LIF, human

MO16101 100 ug
EUR 688

LIF Antibody

36950-100ul 100ul
EUR 252

LIF Antibody

25283-100ul 100ul
EUR 390

LIF siRNA

20-abx922546
  • EUR 551.00
  • EUR 732.00
  • 15 nmol
  • 30 nmol

LIF siRNA

20-abx922547
  • EUR 551.00
  • EUR 732.00
  • 15 nmol
  • 30 nmol

rHu LIF

AK9977-0005 5µg Ask for price

rHu LIF

AK9977-0025 25µg Ask for price

rHu LIF

AK9977-0100 100µg Ask for price

rHu LIF

AK9977-1000 1mg Ask for price

LIF antibody

PAab09804 100 ug
EUR 386

LIF Antibody

5216-100
EUR 316

LIF Antibody

5216-30T
EUR 146

LIF protein

30R-2771 10 ug
EUR 369
Description: Purified recombinant Human LIF protein

LIF protein

30R-2772 10 ug
EUR 489
Description: Purified recombinant Mouse LIF protein

LIF Peptide

6245P 0.05 mg
EUR 164.75
Description: (IN) LIF peptide

LIF Peptide

43-200P 0.1 mg
EUR 338

LIF antibody

70R-12299 100 ug
EUR 403
Description: Rabbit polyclonal LIF antibody

LIF antibody

70R-14100 100 ug
EUR 322
Description: Affinity purified Rabbit polyclonal LIF antibody

LIF antibody

70R-6230 50 ug
EUR 467
Description: Rabbit polyclonal LIF antibody

LIF antibody

70R-51295 100 ul
EUR 244
Description: Purified Polyclonal LIF antibody

LIF Antibody

6245-002mg 0.02 mg
EUR 171.82
Description: LIF Antibody: LIF is a pleiotropic cytokine with roles in several different systems. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, induction of neuronal cell differentiation, regulator of mesenchymal to epithelial conversion during kidney development, and may also have a role in immune tolerance at the maternal-fetal interface. LIF was initially recognized by its ability to induce terminal differentiation of myeloid leukemic cells. It is a member of the IL-6 cytokine superfamily and can be highly glycosylated. LIF signaling is transduced through the LIF-R/gp130 receptor complex, leading to the phosphorylation and activation of the JAK/STAT pathway. Recent evidence shows that LIF inhibits cardiomyogenesis in embryonic stem cells via STAT3 activation.

LIF Antibody

6245-01mg 0.1 mg
EUR 436.42
Description: LIF Antibody: LIF is a pleiotropic cytokine with roles in several different systems. It is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, induction of neuronal cell differentiation, regulator of mesenchymal to epithelial conversion during kidney development, and may also have a role in immune tolerance at the maternal-fetal interface. LIF was initially recognized by its ability to induce terminal differentiation of myeloid leukemic cells. It is a member of the IL-6 cytokine superfamily and can be highly glycosylated. LIF signaling is transduced through the LIF-R/gp130 receptor complex, leading to the phosphorylation and activation of the JAK/STAT pathway. Recent evidence shows that LIF inhibits cardiomyogenesis in embryonic stem cells via STAT3 activation.

Mouse LIF PicoKine ELISA Kit

EK0580 96 wells
EUR 425
Description: For quantitative detection of mouse LIF in cell culture supernates, serum and plasma (heparin, EDTA).

Leukemia Inhibitory Factor (LIF), mouse

PR16102 5 ug
EUR 435

LIF, Mouse Recombinant , 1MIU/ml

L4500-001 1ml
EUR 339

LIF, Mouse Recombinant , 1MIU/ml

L4500-005 5x1ml
EUR 1193

LIF, Mouse Recombinant , 10MIU/ml

L4501-001 1ml
EUR 1454

LIF ELISA Kit (Mouse) (OKEH04045)

OKEH04045 96 Wells
EUR 544
Description: Description of target: LIF has the capacity to induce terminal differentiation in leukemic cells. Its activities include the induction of hematopoietic differentiation in normal and myeloid leukemia cells, the induction of neuronal cell differentiation, and the stimulation of acute-phase protein synthesis in hepatocytes.;Species reactivity: Mouse;Application: ;Assay info: Assay Methodology: Quantitative Sandwich ELISA;Sensitivity: 0.039 ng/mL

LIF ELISA Kit (Mouse) (OKBB00760)

OKBB00760 96 Wells
EUR 505
Description: Description of target: Leukemia inhibitory factor, or LIF, is an interleukin 6 class cytokine that affects cell growth by inhibiting differentiation. When LIF levels drop, the cells differentiate. The LIF was mapped gene to 22q11-q12.2 by Southern analysis of a series of mouse/human somatic cell hybrids and by in situ hybridization to the chromosomes of 2 normal males and some individuals with chromosomal rearrangements. The gene maps between the Philadelphia translocation BCR1 and the breakpoint of the translocation in cell line GM2324 at 22q12.2. LIF derives its name from its ability to induce the terminal differentiation of myeloid leukemic cells, thus preventing their continued growth. Other properties attributed to the cytokine include: the growth promotion and cell differentiation of different types of target cells, influence on bone metabolism, cachexia, neural development, embryogenesis and inflammation.;Species reactivity: Mouse;Application: ELISA;Assay info: ;Sensitivity: <10pg/ml

ELISA kit for Mouse LIF

EK5250 96 tests
EUR 553
Description: Enzyme-linked immunosorbent assay kit for quantification of Mouse LIF in samples from serum, plasma, tissue homogenates and other biological fluids.

Lif ORF Vector (Mouse) (pORF)

ORF049145 1.0 ug DNA
EUR 506

Lif ORF Vector (Mouse) (pORF)

ORF049146 1.0 ug DNA
EUR 506

Human CellExp? LIF, mouse recombinant

7268-10
EUR 370

LIF Polyclonal Antibody

ES3837-100ul 100ul
EUR 279
Description: A Rabbit Polyclonal antibody against LIF from Human. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA

LIF Polyclonal Antibody

ES3837-50ul 50ul
EUR 207
Description: A Rabbit Polyclonal antibody against LIF from Human. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA

Polyclonal LIF Antibody

APR00279G 0.1mg
EUR 484
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human LIF . This antibody is tested and proven to work in the following applications:

Polyclonal LIF Antibody

APR06696G 0.1 mg
EUR 659
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human LIF . This antibody is tested and proven to work in the following applications:

LIF Polyclonal Antibody

ABP52838-003ml 0.03ml
EUR 158
Description: A polyclonal antibody for detection of LIF from Human. This LIF antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the C-terminal region of human LIF